全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Research Progress of c-Kit in Platinum-Resistant Ovarian Cancer

DOI: 10.4236/jbm.2025.132030, PP. 404-412

Keywords: Ovarian Cancer, Platinum Resistance, c-Kit

Full-Text   Cite this paper   Add to My Lib

Abstract:

c-Kit (CD117) is a type IIIa receptor tyrosine kinase (RTK) that plays a key role in regulating the normal physiological processes of cells. In addition, the activation of c-Kit activates the tyrosine kinase signal transduction pathway, which is closely related to the occurrence and development of gynecological tumors, especially ovarian cancer. This article reviews the mechanisms of platinum resistance in ovarian cancer and the research progress of c-Kit in ovarian cancer.

References

[1]  Feng, Z., Guo, Q.H., Zhu, J., et al. (2024) Progress and Prospect of Gynecological Malignant Tumor Treatment in 2023. China Oncology, 34, 340-360.
[2]  Liu, N.N., Song, G.H. and Lu, S.Y. (2023) The Mechanism of Platinum Resistance in Ovarian Cancer and the New Progress of Related Targeted Therapy. Wisdom and Health, 9, 52-55+61.
[3]  Liang, Z.D., Long, Y., Tsai, W.B., et al. (2012) Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. Molecular Cancer Therapeutics, 11, 2483-2494.
https://doi.org/10.1158/1535-7163.MCT-12-0580
[4]  Pan, H.B., Kim, E., Rankin, G.O., et al. (2018) Theaflavin-3,3’-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells. International Journal of Molecular Sciences, 19, Article 117.
https://doi.org/10.3390/ijms19010117
[5]  Kilari, D., Guancial, E. and Kim, E.S. (2016) Role of Copper Transporters in Platinum Resistance. World Journal of Clinical Oncology, 7, 106-113.
https://doi.org/10.5306/wjco.v7.i1.106
[6]  Havasi, A., Cainap, S.S., Havasi, A.T., et al. (2023) Ovarian Cancer—Insights into Platinum Resistance and Overcoming It. Medicina (Kaunas), 59, Article 544.
https://doi.org/10.3390/medicina59030544
[7]  Yang, L., Xie, H.J., Li, Y.Y., et al. (2022) Molecular Mechanisms of Platinum-Based Chemotherapy Resistance in Ovarian Cancer (Review). Oncology Reports, 47, Article 82.
https://doi.org/10.3892/or.2022.8293
[8]  Liu, Y.Z., Shi, L.J., Yuan, C.Z., et al. (2022) Downregulation of ITIH3 Contributes to Cisplatin-Based Chemotherapy Resistance in Ovarian Carcinoma via the Bcl-2 Mediated Anti-apoptosis Signaling Pathway. Oncology Letters, 25, Article 61.
https://doi.org/10.3892/ol.2022.13646
[9]  Nowak, M. and Klink, M. (2020) The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer. Cells, 9, Article 1299.
https://doi.org/10.3390/cells9051299
[10]  Kobayashi, H., Ogawa, K., Kawahara, N., et al. (2017) Sequential Molecular Changes and Dynamic Oxidative Stress in High-Grade Serous Ovarian Carcinogenesis. Free Radical Research, 51, 755-764.
https://doi.org/10.1080/10715762.2017.1383605
[11]  Deng, J.L., Bai, X.P., Feng, X.J., et al. (2019) Inhibition of PI3K/Akt/mTOR Signaling Pathway Alleviates Ovarian Cancer Chemoresistance through Reversing Epithelial-Mesenchymal Transition and Decreasing Cancer Stem Cell Marker Expression. BMC Cancer, 19, Article No. 618.
https://doi.org/10.1186/s12885-019-5824-9
[12]  Sheikh, E., Tran, T., Vranic, S., Levy, A. and Bonfil, R.D. (2022) Role and Significance of c-Kit Receptor Tyrosine Kinase in Cancer: A Review. Bosnian Journal of Basic Medical Sciences, 22, 683-698.
https://doi.org/10.17305/bjbms.2021.7399
[13]  Wang, H., Boussouar, A., Mazelin, L., Tauszig-Delamasure, S., Sun, Y., Goldschneider, D., Paradisi, A. and Mehlen, P. (2018) The Proto-Oncogene c-Kit Inhibits Tumor Growth by Behaving as a Dependence Receptor. Molecular Cell, 72, 413-425.
https://doi.org/10.1016/j.molcel.2018.08.040
[14]  Zaruba, M.M., Soonpaa, M., Reuter, S. and Field, L.J. (2010) Cardiomyogenic Potential of C-Kit+-Expressing Cells Derived from Neonatal and Adult Mouse Hearts. Circulation, 121, 1992-2000.
https://doi.org/10.1161/CIRCULATIONAHA.109.909093
[15]  Tonary, A.M., Macdonald, E.A., Faught, W., et al. (2000) Lack of Expression of c-Kit in Ovarian Cancers is Associated with Poor Prognosis. International Journal of Cancer, 89, 242-250.
https://doi.org/10.1002/1097-0215(20000520)89:3<242::AID-IJC6>3.0.CO;2-6
[16]  Yi, C.J., Li, L., Chen, K.M., et al. (2010) Differences in the Expression of c-Kit and PDGFRα in Epithelial Ovarian Cancer Tumor Cells and Tumor Stroma. China General Medicine, 13, 2628-2630.
[17]  Peng, G.C., Wang, X.W., Yi, C.J. (2016) Clinical Value of Monitoring Peripheral Blood SCF in Predicting Chemotherapy Resistance of c-Kit Positive Epithelial Ovarian Cancer. Progress in Obstetrics and Gynecology, 25, 891-894+899.
[18]  Yi, C.J. (2014) Clinical and Basic Research on c-Kit and Platinum Resistance in Ovarian Cancer. Jingzhou First People’s Hospital.
[19]  Wang, L.N, Tian, X.Y., Mi, J.Q., et al. (2007) Expression and Significance of c-Kit, C-abl, PDGFRα in Ovarian Cancer. Journal of Medical Research, No. 8, 50-52.
[20]  An, Y., An, M.E. and Wu, C.F. (2005) Expression and Clinical Significance of c-Kit in Ovarian Cancer. Journal of Harbin Medical University, No. 5, 405-407+412.
[21]  Brustmann, H. (2005) Immunohistochemical Detection of Human Telomerase Reverse Transcriptase (hTERT) and c-Kit in Serous Ovarian Carcinoma: A Clinicopathologic Study. Gynecologic Oncology, 98, 396-402.
https://doi.org/10.1016/j.ygyno.2005.04.035
[22]  Shaw, T.J., Keszthelyi, E.J., Tonary, A.M., et al. (2002) Cyclic AMP in Ovarian Cancer Cells Both Inhibits Proliferation and Increases c-Kit Expression. Experimental Cell Research, 273, 95-106.
https://doi.org/10.1006/excr.2001.5426
[23]  Raspollini, M.R., Amunni, G., Villanucci, A., et al. (2004) C-Kit Expression and Correlation with Chemotherapy Resistance in Ovarian Carcinoma: An Immunocytochemical Study. Annals of Oncology, 15, 594-597.
https://doi.org/10.1093/annonc/mdh139
[24]  Yi, C., Zhang, L., Li, L., Liu, X., Ling, S., Zhang, F. and Liang, W. (2014) Establishment of an Orthotopic Transplantation Tumor Model in Nude Mice Using a Drug-Resistant Human Ovarian Cancer Cell Line with a High Expression of c-Kit. Oncology Letters, 8, 2611-2615.
https://doi.org/10.3892/ol.2014.2537
[25]  Mazzoldi, E.L., Pavan, S., Pilotto, G., Leone, K., Pagotto, A., Frezzini, S., Nicoletto, M.O., Amadori, A. and Pastò, A. (2019) A Juxtacrine/Paracrine Loop between c-Kit and Stem Cell Factor Promotes Cancer Stem Cell Survival in Epithelial Ovarian Cancer. Cell Death & Disease, 10, Article No. 412.
https://doi.org/10.1038/s41419-019-1656-4
[26]  Fang, C.H., Lin, Y.T., Liang, C.M. and Liang, S.M. (2020) A Novel c-Kit/Phospho-Prohibitin Axis Enhances Ovarian Cancer Stemness and Chemoresistance via Notch3-PBX1 and β-Catenin-ABCG2 Signaling. Journal of Biomedical Science, 27, Article No. 42.
https://doi.org/10.1186/s12929-020-00638-x
[27]  He, G.L. (2004) Expression of c-ABL, c-Kit and Platelet-Derived Growth Factor Receptor-β in Ovarian Serous Carcinoma and Normal Ovarian Epithelium. Journal of Foreign Medicine and Obstetrics and Gynecology, No. 2, 137.
[28]  Sachin, M., Dominic, F., Jerald, J., et al. (2004) Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma. Clinical Cancer Research, 10, 897-908.
https://doi.org/10.1158/1078-0432.CCR-1151-3
[29]  Schilder, R.J., Sill, M.W., Lee, R.B., et al. (2008) Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 26, 3418-3425.
https://doi.org/10.1200/JCO.2007.14.3420
[30]  Safra, T., Andreopoulou, E., Levinson, B., et al. (2010) Weekly Paclitaxel with Intermittent Imatinib Mesylate (Gleevec): Tolerance and Activity in Recurrent Epithelial Ovarian Cancer. Anticancer Research, 30, 3243-3247.
[31]  Zhang, K. and Chen, Y. (2014) Imatinib Mesylate Enhances the Effect of Cisplatin on Drug-Resistant Ovarian Cancer Cells. Practical Drugs and Clinic, 17, 1096-1099.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133